Readoutin 135d
RHEACELL GmbH & Co. KG — allo-APZ2-CVU
Phase 3 primary completion: Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III).
- Date
- Apr 2027
- Type
- Readout
- Indication
- Venous Leg Ulcer
Readoutin 135d
Phase 3 primary completion: Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III).
The weekly brief is free. Pro adds reminders 7 days and 1 day before.